DBS for TRD with the Medtronic Percept PC

Last updated: September 4, 2024
Sponsor: Helen Mayberg, MD
Overall Status: Active - Recruiting

Phase

N/A

Condition

Depression

Depression (Adult And Geriatric)

Depression (Major/severe)

Treatment

Medtronic Percept PC DBS system

Clinical Study ID

NCT05773755
STUDY-22-01731
  • Ages 25-70
  • All Genders

Study Summary

Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which involves placement of electrodes in a specific region of the brain and stimulating that area with electricity. This is believed to reset the brain network responsible for symptoms and results in a significant antidepressant response. A series of open-label studies have demonstrated sustained, long-term antidepressant effects in 40-60% of patients who received this treatment. A challenge to the effective dissemination of this fledgling treatment is the absence of biomarkers (objective, measureable indications of the state of the body and brain) to guide device placement and select stimulation parameters during follow-up care.

By using a DBS device called the Percept PC (Medtronic, Inc) which has the ability to both deliver stimulation to and record electrical signals directly from the brain, this study aims to identify changes in local field potentials (LFPs), specific electrical signals that are thought to represent how the brain communicates information from one region to another, to see how this relates to DBS parameter settings and patient depressive symptomatology. The goal of this study is to study LFPs before and during active DBS stimulation to identify changes that correlate with the antidepressant effects of SCC DBS.

The study team will recruit 10 patients with TRD and implant them with the Percept PC system. Participants will be asked to complete short questionnaires and collect LFP data twice daily for the first year of the study, as well as have weekly in person research procedures and assessments with the study team for up to one year. These include meetings with the study psychiatrist, psychologist, symptom ratings, and movement, voice, and video recordings. A brief discontinuation experiment will be conducted after 6 months of stimulation, in which the stimulation will be turned off and patterns of LFP changes will be recorded. The entire study is expected to last about 5 years, parcellated into several study phases. All participants are required to live in the New York metropolitan area for the first several months of the study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 25-70 years old.

  • Ability to provide written informed consent.

  • Primary psychiatric diagnosis of Major Depressive Disorder (MDD), either singleepisode or recurrent type, without psychotic features, currently experiencing aMajor Depressive Episode (MDE), as diagnosed by Structured Clinical Interview forDSM IV-TR or DSM-5 (SCID-IV or SCID-5). Two independent psychiatrists will confirmthe diagnosis, as well.

  • Current depressive episode of at least two years duration OR a history of more than 3 lifetime depressive episodes.

  • Minimum score at study entry of 20 on the 17-item Hamilton Depression Rating Scale

  • Average pre-operative HDRS-17 score of 20 or greater (averaged over four weeklypre-surgical evaluations during the four weeks prior to surgery)

  • A maximum Global Assessment of Functioning of 50 or less.

  • Confirmed to have treatment-resistant depression (TRD). Treatment-resistance will bedefined as failure to respond to at least four adequate antidepressant treatments (assessed with the Antidepressant Treatment History Form [ATHF-SF] and verifiedthrough medical records) during the current episode. Treatments which support studyinclusion include antidepressive medications, certain augmentation agents,evidenced-based psychotherapy, and neuromodulation (ECT, transcranial magneticstimulation (TMS)). For those patients who have not received ECT, patients may beconsidered eligible for study participation if they have received adequate trials ofan SSRI, SNRI, augmentation agent (certain atypical antipsychotic medications,Lithium), and TMS and/or ketamine.

  • ability comply with study and device management procedures.

Exclusion

Exclusion criteria:

  • Other primary Axis I conditions

  • Active suicidal ideation with intent, suicide attempt within the last six months,more than three suicide attempts within the last two years, or serious suicide riskas determined by the study psychiatrists

  • Other primary neurological disorders or unstable medical illness

  • Conditions requiring anticoagulant therapy which cannot be discontinued for theperioperative period, as required

  • Pregnancy or plan to come pregnant during the study

  • Contraindications for general anesthesia, neurosurgery, or an MRI scan

  • Currently implanted with a cardiac pacemaker / defibrillator or other implantedelectrical device which may interfere with DBS stimulator or the function of whichmay be impacted by its implantation.

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: Medtronic Percept PC DBS system
Phase:
Study Start date:
March 01, 2023
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Icahn School of Medicine at Mount Sinai, Mount Sinai West

    New York, New York 10019
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.